Codexis (CDXS) Interest Expenses (2010 - 2012)

Codexis (CDXS) recorded quarterly Interest Expenses of $157000.0 in Q2 2012, up 33.05% quarter-over-quarter from $118000.0 in Q1 2012, and up 1081.25% on a YoY basis from $13291.0 in Q3 2011.

Codexis (CDXS) Interest Expenses (2010 - 2012) Analysis & Trends

Codexis' Interest Expenses history runs 3 years deep, the most recent figure standing at $157000.0 for Q2 2012.

  • In Q2 2012, Interest Expenses rose 1081.25% year-over-year to $157000.0; the TTM figure through Mar 2013 stood at $157000.0 (down 80.62% YoY), while the FY2011 annual figure was $675000.0, down 43.7% from the prior year.
  • Interest Expenses was $157000.0 for Q2 2012 at Codexis, up from $118000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $654000.0 in Q2 2010 to a low of -$17000.0 in Q1 2011.
  • Historically, Interest Expenses has averaged $199000.0 across 3 years, with a median of $152000.0 in 2010.
  • The sharpest annual moves came in 2011 and 2012: Interest Expenses slumped 102.45% in 2011, then jumped 1081.25% in 2012.
  • A 3-year view of Interest Expenses shows it stood at $152000.0 in 2010, then soared by 95.39% to $297000.0 in 2011, then slumped by 47.14% to $157000.0 in 2012.
  • The last three Interest Expenses figures came in at $157000.0 (Q2 2012), $118000.0 (Q1 2012), and $297000.0 (Q4 2011), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - -
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn -5.50 Mn
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - 61,000.00
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - -332,000.00
7 Psyence Biomedical 238.34 Bn 238.33 Bn - -2,753.00
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn -
9 Abivax 95.45 Bn 95.45 Bn - -5.58 Mn
10 Codexis 226.01 Mn 160.87 Mn 13.18 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2012 157,000.00
Jun 30, 2012 157,000.00
Mar 31, 2012 118,000.00
Mar 31, 2012 118,000.00
Dec 31, 2011 297,000.00
Dec 31, 2011 297,000.00
Sep 30, 2011 411,000.00
Sep 30, 2011 411,000.00
Jun 30, 2011 -16,000.00
Jun 30, 2011 -16,000.00
Mar 31, 2011 -17,000.00
Mar 31, 2011 -17,000.00
Dec 31, 2010 152,000.00
Dec 31, 2010 152,000.00
Sep 30, 2010 35,000.00
Sep 30, 2010 35,000.00
Jun 30, 2010 654,000.00
Jun 30, 2010 654,000.00